Equity (Details) - Schedule of nonvested stock options granted |
9 Months Ended |
|---|---|
|
Sep. 30, 2020
$ / shares
shares
| |
| Schedule of nonvested stock options granted [Abstract] | |
| Number of Options, Nonvested at January 1, 2020 | shares | 264,723 |
| Weighted Average Exercise Price, Nonvested at January 1, 2020 | $ / shares | $ 2.00 |
| Number of Options, Granted | shares | 1,760,000 |
| Weighted Average Exercise Price, Granted | $ / shares | $ 1.57 |
| Number of Options, Vested | shares | (1,523,057) |
| Weighted Average Exercise Price, Vested | $ / shares | $ (1.63) |
| Number of Options, Nonvested at September 30, 2020 | shares | 501,666 |
| Weighted Average Exercise Price, Nonvested at September 30, 2020 | $ / shares | $ 1.59 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|